Abstract.Statins have been confirmed with protective effect to microvessels in diabetic retinopathy, implicated as reducing vascular permeability, maintaining endothelial junction integrity and improving blood perfusion, which are surrogate markers of vascular 'normalization', but no data are currently available on efficacy of statins on tumor endothelial functions. Since statins have been shown to exhibit a biphasic dose-related response on biological behaviour of microvessels, we sought to determine whether statins with bipolar concentrations can ameliorate vessel dysfunction and then increase efficiency of chemotherapeutics in Lewis lung carcinoma and B16F10 melanoma models. Our in vitro study showed that simvastatin reduces hypoxia-induced endothelium leakage in human umbilical vein endothelial cells (HUVEC) in a concentration-dependent manner. In tumor-bearing mice, low-dose simvastatin (0.2 mg/kg) induced upregulation of endothelial NO synthase (eNOS) skewed vessels to a pericyte-coated and stable pattern, while high-dose simvastatin (10 mg/kg) remarkably deceased reactive oxygen species (ROS)-induced hypoxia-inducible factor (HIF-1α) and vascular endothelial growth factor (VEGF) expression, attenuating VEGF-drived tumor vessel hyperpermeability. These changes ultimately improved intratumoral perfusion and decreased tumor hypoxia. Administration of cisplatin and cyclophosphamide to the simvastatin-treated mice resulted in slower tumor growth. Collectively, simvastatin may promote tumor vessel normalization and show clinical benefit when used in combination with chemotherapeutics.
IntroductionPathological angiogenesis and abnormal vessel structures and functions are common features of solid tumors and several non-malignant diseases, such as schwannomas and diabetic retinopathy (DR) (1,2). Vessels in these lesions are highly disorganized and inefficient, and lack pericytes or normal attachment between pericytes and endothelial cells (ECs) (3-5). Such abnormalities of tumor vessels in turn lead to impairment of endothelial barrier function, decreased blood flow and subsequent aggravation of hypoxia in tumor tissues, which result in a poor delivery of anticancer therapeutics and augmentation of radioresistance in tumors. Similar vessel phenotypes are shown in DR characterized by breakdown of the blood-retinal barrier (BRB) that lead to diabetic macular edema and vision loss (6).By correcting the aberrance in morphological structure and function of vessels, we could normalize the microenvironment of retina in favor of disease control and improve response to other therapies (7,8). The strategies for vascular normalization are likely multifaceted. Substantial evidence indicates that anti-angiogenic treatment could achieve this goal by pharmacological inhibition of vascular endothelial growth factor (VEGF) signaling and it has become a widely accepted treatment for several diseases where neovascularization and permeability plays a pivotal role, including cancer and retinal disorders (8,9). Bevacizumab, a humanized...